Charmacy Pharmaceutical Co., Ltd. (HKG:2289)

Charmacy Pharmaceutical Cash Flow Statement

Financials in millions CNY. Fiscal year is January - December.

Operating Activities

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	46.27	53.28	51.34	90.47	23.15
Depreciation & Amortization	29.45	32.17	26.47	30.68	32.03
Other Amortization	6.32	3.85	2.95	2.89	1.73
Loss (Gain) From Sale of Assets	0.18	-0.31	-0.05	-65.84	-0.15
Asset Writedown & Restructuring Costs	-0.01	0.36	-0.01	-	0.01
Loss (Gain) From Sale of Investments	-	-	0.1	-	-0
Provision & Write-off of Bad Debts	13.55	0.07	0.8	2.48	-0.29
Other Operating Activities	51.02	38.14	41.16	36.31	41.71
Change in Accounts Receivable	69.57	-409.63	-98.17	-222.47	-54.81
Change in Inventory	-144.21	116.04	-193.35	-77.74	75.75
Change in Accounts Payable	202.76	272.54	72.25	245.77	-139.9
Operating Cash Flow	270.89	106.04	-96.54	44.05	-19.54
Operating Cash Flow Growth	155.47%	-	-	-	-

Investing Activities

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Capital Expenditures	-7.47	-15.73	-40.85	-8.59	-25.04
Sale of Property, Plant & Equipment	0.38	0.08	80.19	80.35	0.64
Other Investing Activities	-	-	-	-	0
Investing Cash Flow	-7.09	-15.64	39.34	71.76	-24.4

Financing Activities

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Short-Term Debt Issued	3,670	3,688	2,492	2,852	1,807
Long-Term Debt Issued	1,461	1,266	836.6	2.26	974.03
Total Debt Issued	5,131	4,955	3,329	2,855	2,781
Short-Term Debt Repaid	-4,127	-3,883	-2,388	-3,017	-1,830
Long-Term Debt Repaid	-1,139	-1,038	-767.41	-3.58	-824.11
Total Debt Repaid	-5,266	-4,921	-3,156	-3,021	-2,654
Net Debt Issued (Repaid)	-135.36	33.98	172.72	-166.48	126.33
Common Dividends Paid	-80.5	-64.2	-75.5	-28.44	-52.49
Other Financing Activities	1.89	-1.31	4.04	3.71	0.56
Financing Cash Flow	-213.98	-31.54	101.26	-191.21	74.4

Net Cash Flow

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Foreign Exchange Rate Adjustments	-0.01	0.01	0.01	0.03	-
Net Cash Flow	49.81	58.87	44.07	-75.37	30.46

Free Cash Flow

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Free Cash Flow	263.42	90.31	-137.39	35.46	-44.58
Free Cash Flow Growth	191.69%	-	-	-	-
Free Cash Flow Margin	6.01%	2.04%	-3.12%	0.85%	-1.18%
Free Cash Flow Per Share	2.44	0.84	-1.27	0.33	-0.41
Levered Free Cash Flow	-187.13	-68.55	10.27	-145.91	-28.06
Unlevered Free Cash Flow	-151.61	-30.64	36.48	-123.99	-2.12

Additional Metrics

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash Income Tax Paid	51.71	52.98	58.86	36.02	37.42
Change in Working Capital	124.1	-21.53	-219.31	-52.94	-117.74

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 19, 2026

Data Sources Report a data error